What is Brief History of FibroGen Company?

FibroGen Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What is FibroGen's Story?

FibroGen, Inc. is a biopharmaceutical company focused on creating new treatments for serious medical conditions. Their work on anemia, particularly with roxadustat, has been a major development in patient care.

Founded in 1993 in San Francisco, the company aimed to develop therapies for diseases lacking effective treatments. This vision continues to guide their research and development efforts.

A key innovation is roxadustat, an oral treatment for anemia. This development represents a significant step in managing conditions like those in chronic kidney disease patients. The company's history includes strategic adjustments, such as a recent reverse stock split to meet exchange requirements. Their ongoing commitment is to address unmet medical needs through advancements in areas like fibrosis, with pipeline candidates such as pamrevlumab and FG-3246. Discover more about their product pipeline, including the FibroGen BCG Matrix.

FibroGen, Inc. began its journey in 1993 in San Francisco, California, founded by Thomas B. Neff, Ph.D., and Katerina M. Politi, Ph.D. Dr. Neff, who led the company as chairman and CEO for 26 years, envisioned a future where debilitating diseases like fibrosis, then lacking effective treatments, could be addressed through scientific innovation.

FibroGen's Founding Story

Established in 1993, FibroGen's founding was driven by a mission to tackle serious unmet medical needs, particularly in the area of fibrosis. The company's early focus on scientific discovery and development laid the groundwork for its future therapeutic advancements.

• Founded in San Francisco, California in 1993.
• Key founders: Thomas B. Neff, Ph.D., and Katerina M. Politi, Ph.D.
• Dr. Neff served as Chairman and CEO for 26 years.
• Initial focus on diseases with limited treatment options, like fibrosis.
• Secured $12 million in seed funding from prominent venture capital firms.
• Early business model centered on discovery, development, and commercialization of therapeutics.
• The company's Mission, Vision & Core Values of FibroGen guided its early development.

FibroGen SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early history of the company was defined by a strong commitment to innovation in treating chronic diseases. Significant investment in research and development fueled the progression of novel therapies, particularly for anemia associated with chronic kidney disease and fibrotic conditions.

Roxadustat Development and First Approvals

A central focus was the development of roxadustat, an oral HIF-PH inhibitor. This drug achieved a major milestone in December 2018 with its first global marketing authorization in China for anemia in dialysis-dependent CKD patients. Subsequently, it received approval in China for non-dialysis-dependent CKD patients as well.

Global Expansion Through Partnerships

The company strategically expanded its international presence through key collaborations. Partnerships with major pharmaceutical companies facilitated broader market access and generated significant revenue through milestone payments, such as the $50 million received from one partner in February 2020.

Pipeline Advancement and R&D Investment

Beyond roxadustat, the company advanced its pipeline with pamrevlumab, an antibody targeting CTGF, entering Phase 3 trials for idiopathic pulmonary fibrosis and pancreatic cancer. This commitment to research is reflected in cumulative expenditures of approximately $3.3 billion through December 31, 2024.

Financial Performance and Liquidity

For the full year 2024, total revenue from continuing operations was $29.6 million, a decrease from $46.8 million in 2023, indicating evolving revenue streams. As of March 31, 2025, the company maintained $128.4 million in cash, cash equivalents, and accounts receivable, with $33.8 million held in the U.S. This period highlights the company's early Growth Strategy of FibroGen.

FibroGen PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

FibroGen's journey is marked by significant advancements in drug development, particularly focusing on hypoxia-inducible factor (HIF) biology, leading to groundbreaking therapies. The company's history is a testament to its commitment to addressing unmet medical needs through scientific innovation.

FibroGen's primary innovation is roxadustat, the first orally administered small molecule HIF-PH inhibitor, which has gained approvals for anemia in CKD patients across China, Europe, and Japan. Another key development is FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer, showing promising Phase 1 results with a median radiographic progression-free survival of 8.7 months.

Roxadustat: Oral HIF-PH Inhibitor

Roxadustat represents a significant advancement as the first orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). Its development targets anemia associated with chronic kidney disease (CKD).

FG-3246: CD46-Targeting ADC

FG-3246 is an antibody-drug conjugate (ADC) designed to target CD46, a protein found on cancer cells. It is currently under investigation for metastatic castration-resistant prostate cancer (mCRPC).

FG-3165: Galectin-9 Monoclonal Antibody

FG-3165 is a monoclonal antibody that targets galectin-9, a protein implicated in various cancers. The company has received FDA clearance for an Investigational New Drug (IND) application for this therapy.

FibroGen has encountered significant challenges, notably the U.S. FDA advisory committee's negative recommendation for roxadustat in CKD-associated anemia, impacting its U.S. market entry for this indication. Financially, the company reported a substantial revenue decrease in Q1 2025 compared to Q1 2024, largely due to the divestiture of FibroGen China, though this move is expected to improve its cash runway.

U.S. Regulatory Setback for Roxadustat

The U.S. FDA Cardiovascular and Renal Drugs Advisory Committee's vote against recommending roxadustat for CKD-associated anemia in July 2021 presented a major hurdle. This decision significantly complicated the drug's path to U.S. approval for this specific use.

Financial Performance and Restructuring

A notable financial challenge was the decrease in total revenue from $25.4 million in Q1 2024 to $2.7 million in Q1 2025, primarily due to the divestiture of FibroGen China. The company also undertook a reverse stock split to comply with Nasdaq listing requirements.

Ongoing Development for LR-MDS

Despite the U.S. setback for CKD anemia, FibroGen is actively pursuing roxadustat for anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). The company submitted a Type C meeting request to the FDA in Q1 2025 to discuss a potential Phase 3 program.

FibroGen Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The FibroGen company history is a narrative of scientific pursuit and strategic adaptation, from its FibroGen founding to its current focus on advancing its oncology pipeline. The company's evolution reflects key milestones in drug development and regulatory navigation.

Advancing Oncology Pipeline

FibroGen's future is significantly focused on its oncology pipeline, particularly FG-3246 for mCRPC. This strategic direction aims to leverage the company's research capabilities in a key therapeutic area.

Exploring New Indications for Roxadustat

The company is also exploring the potential for roxadustat in new indications, such as LR-MDS in the U.S. This expansion of roxadustat's utility is a key part of its ongoing development strategy.

Strategic Divestiture and Financial Runway

The divestiture of its China operations is a strategic move to streamline the company and extend its financial runway into H2 2027. This will provide a stronger financial footing for U.S. development initiatives.

Analyst Projections and Stock Value

Analysts project a potential increase in FibroGen's stock value, with forecasts suggesting an average price of $13.18 in 2025 and potentially reaching $9.58 by 2030. This outlook reflects confidence in the company's strategic direction and Marketing Strategy of FibroGen.

FibroGen Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔